Merck & Co’s Carisma Therapeutics CARM Stock Holding History

Merck & Co’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,473,240	Closed	-$47.9K	–	14
2026 Q1	$47.9K	Hold	1,473,240	–	–	0.01%	12
2025 Q4	$63.3K	Hold	1,473,240	–	–	0.02%	10
2025 Q3	$404K	Hold	1,473,240	–	–	0.18%	11
2025 Q2	$577K	Hold	1,473,240	–	–	0.27%	11
2025 Q1	$457K	Hold	1,473,240	–	–	0.28%	11
2024 Q4	$617K	Buy	+1,473,240	New	+$1.21M	0.24%	11

Other funds holding CARM

UBP

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

Merck & Co's CARM Position: Q2 2026 in Review

Merck & Co sold out of Carisma Therapeutics (CARM) in Q2 2026, closing a stake of 1,473,240 shares — an estimated $47.9K sold.

Merck & Co first reported a position in CARM in Q4 2024 and held it in 6 quarters. The position peaked at $617K in Q4 2024. 1 fund tracked by Wall St. Rank holds CARM as of Q2 2026.

Merck & Co reported no remaining Carisma Therapeutics position as of Q2 2026 after selling out during the quarter.
Merck & Co sold 1,473,240 Carisma Therapeutics shares in Q2 2026, an estimated $47.9K.
Merck & Co first reported a position in Carisma Therapeutics in Q4 2024 and held it in 6 quarters.
Merck & Co's Carisma Therapeutics position peaked at $617K in Q4 2024.
1 fund tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2026.

Based on Merck & Co's 13F filing for Q2 2026, filed 7 Aug 2026.